The long-term study completed by researchers at NYU Langone Medical Center tracked 213 adults with and without SCI over an average of seven years, with data collection taking nearly two decades. Further cognitive decline to MCI or dementia was observed in 54 percent of SCI persons, while only in 15 percent of persons free of SCI.
“This is the first study to use mild cognitive impairment as well as dementia as an outcome criterion to demonstrate the outcome of SCI as a possible forerunner of eventual Alzheimer’s disease,” said Barry Reisberg, MD, professor of psychiatry, director of the Fisher Alzheimer’s Disease Program and director, Clinical Core, NYU Alzheimer’s Disease Center at NYU Langone Medical Center. “The findings indicate that a significant percentage of people with early subjective symptoms may experience further cognitive decline, whereas few persons without these symptoms decline. If decline does occur in those without SCI symptoms, it takes considerably longer than for those with subjective cognitive symptoms.”
According to the authors, scientists and physicians can now target the prevention of eventual Alzheimer’s disease in the SCI stage, beginning more than 20 years before dementia becomes evident.
“These intriguing results more fully describe the possible relationship between early signs of memory loss and development of more serious impairment. This is critical to know, as we look for ways to define who is at risk and for whom the earliest interventions might be successful,” said Neil Buckholtz, PhD, National Institute on Aging (NIA), which supported the research. “These findings also underscore the importance of clinicians’ asking about, and listening to, concerns regarding changes in cognition and memory among their aging patients.”
Co-authors of Dr. Reisberg at the NYU Alzheimer’s Disease Center include Melanie B. Shulman, MD, Carol Torossian, PsyD, and Wei Zhu, PhD.
Primary funding for this study was provided by the NIA, which is part of the National Institutes of Health. Additional funding was provided by Mr. Leonard Litwin and the Fisher Center for Alzheimer’s Research Foundation.
212-404-3555 (office) | 212-404-3753 (direct) | 917-301-5699 (cell)